AFRM
Affirm Holdings, Inc.
AFRM's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over AFRM overall, supported by stronger valuation and stronger modeled upside.
AFRM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Weak |
AFRM's revenue, profitability and cash flow are currently healthy, but its balance sheet is weak.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
AFRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $65.84 | — |
| Cheap | 14x | $82.33 | +25% |
| Forward | 30x | $65.84 | — |
| Fair | 68x | $393 | +497% |
| Expensive | 113x | $651 | +889% |
Historical ranges are pointers, not guarantees.
AFRM's PE is 11x, but its earnings don't support one, so it isn't a reliable read right now.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
AFRM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for AFRM, with profitability improving. However, they disagree widely on these estimates.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
AFRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.20 | -62% |
| Q3 2026 | $5.77 | +736% |
| Q2 2026 | $5.53 | +3587% |
| Q1 2026 | $1.12 | +$1.32 |
| Q4 2025 | $0.83 | +$1.47 |
| Q3 2025 | $0.69 | +$2.10 |
| Q2 2025 | $0.15 | +$1.82 |
| Q1 2025 | -$0.20 | +$2.03 |
| Q4 2024 | -$0.64 | +$1.85 |
AFRM's earnings per share have climbed steadily: $5.77 over the past year, about eight times what it earned the year before, and higher year over year for 12 quarters in a row. Its recent earnings include one-off gains.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA's earnings per share have climbed steadily: $7.91 over the past year, up 125% from the year before, and higher year over year for 13 quarters in a row.
AFRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +35% |
| Q2 2026 | $1.2B | +33% |
| Q1 2026 | $1B | +33% |
| Q4 2025 | $1.1B | +30% |
| Q3 2025 | $933.3M | +34% |
| Q2 2025 | $876.4M | +33% |
| Q1 2025 | $783.1M | +36% |
| Q4 2024 | $866.4M | +47% |
AFRM's revenue has grown year over year every quarter since late 2020: $1.3B last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +8 points |
| Q2 2026 | 13% | +6 points |
| Q1 2026 | 8.5% | +9.6 points |
| Q4 2025 | 10% | +11 points |
| Q3 2025 | 6.8% | +26 points |
| Q2 2025 | 6.6% | +18 points |
| Q1 2025 | -1.1% | +27 points |
| Q4 2024 | -0.5% | +29 points |
AFRM's operating margin was 15% last quarter, up 8 points from the same quarter a year ago, near the top of its range since 2019.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over AFRM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over AFRM on profitability, with a higher operating margin.
AFRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $144.6M | -55% |
| Q2 2026 | $229.3M | +875% |
| Q1 2026 | $325.1M | +107% |
| Q4 2025 | $118M | -56% |
| Q3 2025 | $320.2M | +110% |
| Q2 2025 | $23.5M | -23% |
| Q1 2025 | $157.4M | -2.7% |
| Q4 2024 | $268.1M | +654% |
AFRM generated $817M in free cash flow over the past year, up 6.2% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over AFRM on cash flow, with more consistent year-over-year improvement.
AFRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +2.9M shares |
| 1 year | +1% | +3.5M shares |
| 3 years | +16% | +47.9M shares |
| 5 years | +29% | +80.1M shares |
| Available history | +68% | +142M shares |
AFRM has 352M diluted shares, up 1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over AFRM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
AFRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.5x | High |
| Q2 2026 | 11.3x | High |
| Q1 2026 | 11.8x | High |
| Q4 2025 | 15.1x | High |
| Q3 2025 | 17.9x | High |
| Q2 2025 | 45.4x | High |
| Q1 2025 | 755.3x | High |
AFRM's net debt is about 9.5 years of its operating earnings (EBITDA), down from 18 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over AFRM on leverage, with a lower net debt burden relative to earnings.
AFRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.8 | Neutral |
| Stochastic | 14.7 | Oversold |
AFRM's weekly RSI is 45 (neutral) and its Stochastic is 15 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
AFRM PE vs Technology Sector
| Metric | AFRM | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 59% below |
| PE % | 0 | 40 | 40 pts below |
AFRM has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
AFRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.8 | 8.3% below |
| 20 week MA | $74.2 | 11% below |
| 50 week MA | $67.3 | 2.2% below |
| 100 week MA | $65.8 | 0% above |
| 200 week MA | $47.4 | 39% above |
AFRM has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
AFRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $117.0 | $101.2 | -14% |
| 2022 | $101.2 | $9.19 | -91% |
| 2023 | $9.19 | $49.1 | +435% |
| 2024 | $49.1 | $64.6 | +32% |
| 2025 | $64.6 | $75.8 | +17% |
| 2026 YTD | $75.8 | $65.8 | -13% |
AFRM's yearly returns have swung widely, from +435% in 2023 to −91% in 2022. It's down 13% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over AFRM on returns for 2026, with the stronger performance.